- Home
- / Citius Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Citius Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.4
2024-10-29
Market Capitalization
$70.6 M
2024-10-29
Revenue
$90 K
FY, 2022
CreditSafe Score
?
Score changed on Jul 17, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.0K | 90.0K | 90.0K | 90.0K | ||||||
| General and administrative expense | 3.8M | 6.1M | 6.4M | 6.3M | 8.1M | 9.8M | 11.8M | 15.3M | 18.2M | 18.5M |
| Operating expense total | 7.4M | 10.0M | 13.8M | 14.9M | 16.9M | 29.7M | 30.1M | 30.2M | 27.7M | |
| EBIT | (7.4M) | (10.0M) | (13.8M) | (15.6M) | (17.7M) | (23.5M) | (33.3M) | (36.7M) | (42.0M) | (38.5M) |
| EBIT margin, % | -17331.5% | -19678.5% | -37017.8% | |||||||
| Interest income | 806.0 | 52.7K | 68.1K | 261.8K | 251.4K | 1.2M | 758.0K | 110.1K | ||
| Interest expense | 9.0K | 850.8K | 15.8K | 36.2K | ||||||
| Pre tax profit | (8.3M) | (10.4M) | (12.5M) | 15.6M | (17.5M) | (33.1M) | (32.0M) | (38.8M) | (38.7M) | |
| Income tax expense | 1.2K | 576.0K | 576.0K | 576.0K | 1.1M | |||||
| Net Income | (8.3M) | (10.4M) | (12.5M) | (15.6M) | (17.5M) | (23.1M) | (33.6M) | (32.5M) | (39.4M) | (39.7M) |
| EPS | (0.2) | (6.0) | (3.4) |